Steve R Ritland

20020156118, Oct 24, 2002

Jan 23, 2002

10/055451

Lars Breimer - Danbury CT, US
Kapil Dhingra - Tenafly NJ, US
Urvashi Dhingra - Cedar Grove NJ, US
Steve Ritland - Paterson NJ, US

A61K031/404
A61K031/337

514/414000, 514/449000

Disclosed is a method of treating a patient suffering from cancer. The method comprises administering to a patient over a period of up to about 15 days a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a compound of formula I or a pharmaceutically acceptable salt or ester of said compound. The second component consists of an injection solution containing as an active ingredient paclitaxel. The amount of each component in the combination is such that the combination is therapeutically effective. The components are administered concomitantly or sequentially in a three week to four week treatment cycle for as long as the tumor remains under control and the patient tolerates the regimen.

20030013752, Jan 16, 2003

Jun 12, 2002

10/170080

Lars Breimer - Danbury CT, US
Kapil Dhingra - Tenafly NJ, US
Urvashi Dhingra - Cedar Grove NJ, US
Steve Ritland - Paterson NJ, US

A61K031/405

514/414000

A method of treating a patient suffering from cancer comprising administering to the patient a compound of formula I or a therapeutically effective salt or ester thereof, in an amount from about 140 mg/m/day to about 400 mg/m/day for an administration period of up to about 14 days, said administration period starting on the first day of a 21-28 day treatment cycle, said treatment cycle being repeated three to four weeks for as long as the tumor remains under control and the regimen is clinically tolerated.

20030139373, Jul 24, 2003

Nov 8, 2002

10/290652

Lars Breimer - Chatham NJ, US
Kapil Dhingra - Tenafly NJ, US
Urvashi Dhingra - Cedar Grove NJ, US
Steve Ritland - Paterson NJ, US

A61K031/7072
A61K031/404

514/049000, 514/414000

Disclosed are compositions and a method of treating a patient suffering from cancer. The method comprises administering to a patient over a period of up to about 15 days a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a compound of formula I or a pharmaceutically acceptable salt or ester of said compound. The second component consists of an injection solution containing as an active ingredient gemcitabine. The amount of each component in the combination is such that the combination is therapeutically effective. The components are administered concomitantly or sequentially in a three week to four week treatment cycle for as long as the tumor remains under control and the patient tolerates the regimen. The compositions comprise an antineoplastic combination of a compound for formula I and gemcitabine.